Advancements in Dermatology: A Weekly Review
Dermatologia e Venerologia
Cutting-Edge Dermatology: From Urticaria to Alopecia Advances
This week we explore groundbreaking dermatology research including novel treatments for chronic urticaria, hidradenitis suppurativa, and androgenetic alopecia, plus insights into phenotype switching and hereditary angioedema management.
Bibliography
1. Randomized dose-finding study of anti-KIT barzolvolimab in patients with chronic spontaneous urticaria.
Authors: Metz M, Mitha E, Leflein J, et al.
Journal: The Journal of allergy and clinical immunology, 2026 Nov
PMID: 41747871
DOI: 10.1016/j.jaci.2026.02.018
2. Targeting an IL-17/IL-36 pathogenic hub in hidradenitis suppurativa with a bispecific antibody.
Authors: Sun Y, Mi Z, Yu Y, et al.
Journal: Signal transduction and targeted therapy, 2026 Oct 14
PMID: 42869887
DOI: 10.1038/s41392-026-02886-z
3. Safety and pharmacokinetics of anumigilimab for hidradenitis suppurativa or palmoplantar pustulosis: A phase 1b study.
Authors: Kern JS, Thomsen SF, Kokolakis G, et al.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV, 2026 Nov
PMID: 42478283
DOI: 10.1111/jdv.70594
4. Microbiome-derived TOPOSCORE is associated with response to immune checkpoint inhibitor re-induction after chemotherapy in primary resistant metastatic melanoma.
Authors: Haferkamp S, Schilling B, Baumgart L, et al.
Journal: Cancer immunology, immunotherapy : CII, 2026 Oct 30
PMID: 42965706
DOI: 10.1007/s00262-026-04618-2
5. Thulium laser-assisted delivery of growth factors for treating androgenetic alopecia - a randomized, controlled, clinical study.
Authors: Nguyen L, Schneider SW, Herberger K
Journal: Lasers in medical science, 2026 Oct 22
PMID: 42911445
DOI: 10.1007/s10103-026-05066-1
6. Treatment-associated phenotype switching between psoriasis and atopic dermatitis.
Authors: Torres T, Valenti M, Balato A, et al.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV, 2026 Nov
PMID: 42132049
DOI: 10.1111/jdv.70503
7. Smartphone Applications in Dermatology With Special Focus on AI: A European-Continent-Based Review.
Authors: Sangers T, Shifai AN, Pasqualini DGJ, et al.
Journal: International journal of dermatology, 2026 Nov
PMID: 42458765
DOI: 10.1111/ijd.70582
8. Oral deucrictibant for on-demand treatment of hereditary angioedema attacks: a phase 3, multicentre, randomised, double-blind, placebo-controlled crossover trial.
Authors: Riedl MA, Li PH, Adatia A, et al.
Journal: Lancet (London, England), 2026 Oct 24
PMID: 42849489
DOI: 10.1016/S0140-6736(26)01296-1
9. Extracorporeal photopheresis for the treatment of steroid-refractory immune related adverse events from immune checkpoint inhibitor therapy: a multi-center phase Ib/II clinical trial.
Authors: Riemer R, Braun LM, Giesler S, et al.
Journal: Nature communications, 2026 Oct 23
PMID: 42919851
DOI: 10.1038/s41467-026-78897-9
10. Beyond the first graft: skin cancer risk and risk stratification in retransplanted solid organ recipients.
Authors: Rünger A, Geusau A, Nägeli M, et al.
Journal: The British journal of dermatology, 2026 Oct 19
PMID: 42455021
DOI: 10.1093/bjd/ljag286
Authors: Metz M, Mitha E, Leflein J, et al.
Journal: The Journal of allergy and clinical immunology, 2026 Nov
PMID: 41747871
DOI: 10.1016/j.jaci.2026.02.018
2. Targeting an IL-17/IL-36 pathogenic hub in hidradenitis suppurativa with a bispecific antibody.
Authors: Sun Y, Mi Z, Yu Y, et al.
Journal: Signal transduction and targeted therapy, 2026 Oct 14
PMID: 42869887
DOI: 10.1038/s41392-026-02886-z
3. Safety and pharmacokinetics of anumigilimab for hidradenitis suppurativa or palmoplantar pustulosis: A phase 1b study.
Authors: Kern JS, Thomsen SF, Kokolakis G, et al.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV, 2026 Nov
PMID: 42478283
DOI: 10.1111/jdv.70594
4. Microbiome-derived TOPOSCORE is associated with response to immune checkpoint inhibitor re-induction after chemotherapy in primary resistant metastatic melanoma.
Authors: Haferkamp S, Schilling B, Baumgart L, et al.
Journal: Cancer immunology, immunotherapy : CII, 2026 Oct 30
PMID: 42965706
DOI: 10.1007/s00262-026-04618-2
5. Thulium laser-assisted delivery of growth factors for treating androgenetic alopecia - a randomized, controlled, clinical study.
Authors: Nguyen L, Schneider SW, Herberger K
Journal: Lasers in medical science, 2026 Oct 22
PMID: 42911445
DOI: 10.1007/s10103-026-05066-1
6. Treatment-associated phenotype switching between psoriasis and atopic dermatitis.
Authors: Torres T, Valenti M, Balato A, et al.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV, 2026 Nov
PMID: 42132049
DOI: 10.1111/jdv.70503
7. Smartphone Applications in Dermatology With Special Focus on AI: A European-Continent-Based Review.
Authors: Sangers T, Shifai AN, Pasqualini DGJ, et al.
Journal: International journal of dermatology, 2026 Nov
PMID: 42458765
DOI: 10.1111/ijd.70582
8. Oral deucrictibant for on-demand treatment of hereditary angioedema attacks: a phase 3, multicentre, randomised, double-blind, placebo-controlled crossover trial.
Authors: Riedl MA, Li PH, Adatia A, et al.
Journal: Lancet (London, England), 2026 Oct 24
PMID: 42849489
DOI: 10.1016/S0140-6736(26)01296-1
9. Extracorporeal photopheresis for the treatment of steroid-refractory immune related adverse events from immune checkpoint inhibitor therapy: a multi-center phase Ib/II clinical trial.
Authors: Riemer R, Braun LM, Giesler S, et al.
Journal: Nature communications, 2026 Oct 23
PMID: 42919851
DOI: 10.1038/s41467-026-78897-9
10. Beyond the first graft: skin cancer risk and risk stratification in retransplanted solid organ recipients.
Authors: Rünger A, Geusau A, Nägeli M, et al.
Journal: The British journal of dermatology, 2026 Oct 19
PMID: 42455021
DOI: 10.1093/bjd/ljag286
